Zetia (Ezetimibe) Patent Expiration, LOE Window & CMS Spending

Zetia (Ezetimibe) by Organon: FDA Orange Book LOE 2026-04-30, 11 AB generics, $7.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOrganon
FDA Application & PathwayN021445 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-04-30
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$7.4M
2024 Medicare Part D Spend$5.8M
2024 Medicaid Spend$1.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Organon across sibling Meru public-data platforms.